Major JM, et al. - Experts attempted to examine whether entacapone is linked with prostate cancer and to evaluate whether the relationships are correlated with advanced disease at the time of cancer diagnosis. Between January 2000 and December 2014, new-user cohorts were created of Parkinson's disease (PD) patients treated with add-on entacapone or add-on dopamine agonist/monoamine oxidase B inhibitors by using data from the Department of Veterans Affairs healthcare system. The consequences of this study demonstrated that prolonged therapy with entacapone was not correlated with increased prostate cancer incidence. A higher severity of prostate cancer was also noted.